Capricor Therapeutics Inc. – Filings and Transcripts

NASDAQ: CAPR
Share price (9/4/26): $9.40
Market cap (9/4/26): $547 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement

Prospectus supplement for primary offering

Shelf registration

Ownership Filter

Millennium Management LLC

Tang Capital Management LLC

State Street Corporation

Ra Capital Management, L.P.

Bergmann Anthony

News Filter

Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Provides Update on FDA Advisory Committee Meeting for Deramiocel

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Material Definitive Agreement, New Financial Obligation or Off-Balance Sheet Arrangement

Proxies Filter

Definitive proxy

Preliminary proxy

Definitive proxy

Definitive proxy

Preliminary proxy

Other Filter

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Scanned paper annual report submission